ResMed Inc. at Morgan Stanley Global Healthcare Conference Transcript

Sep 15, 2026 / 02:00PM GMT
Release Date Price: €203.5
David Bailey
Morgan Stanley & Co Ltd - Equity Analyst

Okay. Good morning, everyone. My name is David Bailey. I'm part of the healthcare team at Morgan Stanley, joined today by Mick Farrell and Aaron Bloomer from ResMed. Welcome to you both. Great to have you here.

Before we begin, there are some disclosures. Please see the Morgan Stanley Research Disclosures website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Thanks very much again for coming today. Great to see you in person. Topics-wise, we might go through growth, competition, GLP-1s, margins and strategy as broad topics. We'll see how we go in 35 minutes.

Michael Farrell
ResMed Inc. - Chairman of the Board

Yeah.

Questions & Answers

David Bailey
Morgan Stanley & Co Ltd - Equity Analyst

Maybe just to begin, as we look back over the past five years, Mick, very strong growth across the business from a revenue perspective. US devices, I did

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot